NKTR | Nektar Therapeutics

Index- P/E- EPS (ttm)-2.21 Insider Own1.50% Shs Outstand188.88M Perf Week-5.54%
Market Cap107.45M Forward P/E- EPS next Y-0.69 Insider Trans-3.04% Shs Float185.37M Perf Month-22.01%
Income-414.80M PEG- EPS next Q-0.28 Inst Own94.80% Short Float / Ratio5.45% / 2.02 Perf Quarter-50.84%
Sales88.80M P/S1.21 EPS this Y31.20% Inst Trans-4.28% Short Interest10.10M Perf Half Y-79.90%
Book/sh1.28 P/B0.46 EPS next Y47.90% ROA-56.90% Target Price2.38 Perf Year-84.27%
Cash/sh2.49 P/C0.24 EPS next 5Y-7.30% ROE-112.20% 52W Range0.58 - 5.18 Perf YTD-74.12%
Dividend- P/FCF- EPS past 5Y-32.10% ROI-103.50% 52W High-88.71% Beta1.09
Dividend %- Quick Ratio7.90 Sales past 5Y-21.40% Gross Margin73.70% 52W Low0.84% ATR0.05
Employees216 Current Ratio8.20 Sales Q/Q-12.90% Oper. Margin- RSI (14)32.67 Volatility4.11% 6.23%
OptionableYes Debt/Eq0.00 EPS Q/Q-49.20% Profit Margin- Rel Volume0.61 Prev Close0.60
ShortableYes LT Debt/Eq0.00 EarningsMay 09 AMC Payout- Avg Volume5.00M Price0.58
Recom3.30 SMA20-11.46% SMA50-22.23% SMA200-74.99% Volume3,025,073 Change-2.90%
Date Action Analyst Rating Change Price Target Change
May-10-23Upgrade Jefferies Underperform → Hold $1.50 → $1
Feb-24-23Downgrade Jefferies Hold → Underperform $3.20 → $1.50
Aug-08-22Downgrade JP Morgan Neutral → Underweight
May-31-22Resumed Jefferies Hold $12 → $4
Apr-18-22Downgrade Goldman Neutral → Sell $3
Mar-15-22Downgrade Mizuho Buy → Neutral $35 → $8
Mar-15-22Downgrade Cowen Outperform → Market Perform
Mar-14-22Downgrade William Blair Outperform → Mkt Perform
Mar-14-22Downgrade Stifel Buy → Hold $24 → $5
Mar-14-22Downgrade BTIG Research Buy → Neutral
Jun-08-23 12:55PM
May-10-23 11:28AM
May-09-23 06:45PM
05:41PM Loading…
May-08-23 09:29AM
May-04-23 10:00AM
May-02-23 10:01AM
Apr-27-23 08:30AM
Apr-19-23 08:38AM
Apr-17-23 05:00PM
Apr-16-23 06:30AM
Apr-13-23 10:59AM
08:57AM Loading…
Apr-11-23 08:57AM
Apr-10-23 10:07AM
Apr-02-23 08:27AM
Mar-30-23 11:30AM
Mar-29-23 05:44PM
Mar-24-23 12:00PM
Mar-22-23 09:35AM
Mar-14-23 03:43AM
Feb-28-23 05:15PM
Feb-24-23 10:23AM
Feb-23-23 06:20PM
Jan-09-23 09:04AM
09:00AM Loading…
Jan-04-23 09:00AM
Dec-12-22 10:05AM
Dec-05-22 08:00AM
Nov-10-22 09:05AM
Nov-09-22 09:00AM
Nov-04-22 12:35PM
Nov-03-22 06:35PM
Oct-28-22 10:00AM
Oct-27-22 10:02AM
Oct-25-22 06:00PM
Oct-24-22 07:55AM
Oct-11-22 05:13PM
Oct-07-22 03:42PM
Sep-07-22 01:15AM
Aug-21-22 09:57AM
Aug-16-22 08:30AM
Aug-05-22 12:11PM
Aug-04-22 06:15PM
Jul-26-22 06:00PM
Jul-14-22 06:01AM
Jul-01-22 06:30AM
May-27-22 08:00AM
May-16-22 02:09PM
May-06-22 10:07AM
May-05-22 05:55PM
May-04-22 08:15AM
Apr-28-22 03:02PM
Apr-27-22 12:00PM
Apr-26-22 09:19AM
Apr-25-22 06:00PM
Apr-22-22 08:30AM
Apr-20-22 12:54PM
Apr-18-22 05:25PM
Apr-14-22 04:42PM
Apr-05-22 05:50AM
Mar-30-22 11:30AM
Mar-16-22 12:32PM
Mar-15-22 10:38AM
Mar-14-22 05:43PM
Mar-04-22 09:22AM
Mar-01-22 10:43AM
Feb-28-22 05:35PM
Feb-17-22 06:00PM
Feb-08-22 09:38AM
Feb-03-22 01:38PM
Jan-31-22 03:35PM
Jan-21-22 01:38PM
Jan-20-22 09:38PM
Jan-19-22 01:38PM
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROBIN HOWARD WPresident & CEOMay 16Sale0.7220,36114,660939,797May 17 08:27 PM
Zalevsky JonathanChief R&D OfficerMay 16Sale0.729,7917,050293,388May 17 08:29 PM
Wilson Mark AndrewChief Legal OfficerMay 16Sale0.727,5435,431257,680May 17 08:28 PM
ROBIN HOWARD WPresident & CEOFeb 16Sale3.0019,63558,905960,158Feb 17 08:57 PM
Zalevsky JonathanChief R&D OfficerFeb 16Sale3.0010,48431,452303,179Feb 17 09:00 PM
Thomsen Jillian B.Chief Financial OfficerFeb 16Sale3.0010,26730,801313,497Feb 17 08:58 PM
Wilson Mark AndrewChief Legal OfficerFeb 16Sale3.008,27524,825265,223Feb 17 08:59 PM
ROBIN HOWARD WPresident & CEONov 16Sale3.5738,014135,710979,793Nov 18 06:02 PM
Zalevsky JonathanChief R&D OfficerNov 16Sale3.5713,46048,052313,663Nov 18 06:05 PM
Thomsen Jillian B.Chief Financial OfficerNov 16Sale3.5711,09539,609323,764Nov 18 06:03 PM
Wilson Mark AndrewChief Legal OfficerNov 16Sale3.578,69031,023272,498Nov 18 06:04 PM
Curet MyriamDirectorSep 23Sale3.164,19813,26631,777Sep 26 07:32 PM
Ajer Jeffrey RobertDirectorSep 23Sale3.164,19813,26638,512Sep 26 07:25 PM
CHESS ROBERTDirectorSep 22Sale3.195,10016,269228,179Sep 26 07:23 PM
EASTHAM KARINDirectorSep 13Sale3.6121,26776,77413,033Sep 14 06:01 PM
Zalevsky JonathanChief R&D OfficerAug 18Sale4.6573,716342,779327,123Aug 19 06:27 PM
ROBIN HOWARD WPresident & CEOAug 16Sale4.7613,75965,4931,017,807Aug 17 07:39 PM
Zalevsky JonathanChief R&D OfficerAug 16Sale4.7610,56050,266400,839Aug 17 07:41 PM
Wilson Mark AndrewSVP & General CounselAug 16Sale4.763,18915,180281,188Aug 17 07:40 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerAug 16Sale4.762,0069,549334,859Aug 17 07:40 PM